Calliditas Therapeutics Shares Positive Safety Data for Setanaxib at ASN Kidney Week Calliditas Therapeutics presented key safety data for Setanaxib in Alport syndrome patients at ASN Kidney Week, demonstrating promising results.

Calliditas Therapeutics Shares Positive Safety Data for Setanaxib at ASN Kidney Week #Sweden #Stockholm #Alport_Syndrome #Calliditas_Therapeutics #Setanaxib